Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.

ABSTRACT:

Background

The methylation SEPT9 (mSEPT9) appeared to be effective for hepatocellular carcinoma (HCC) detection. However, its performance in high-risk population has not been validated. We designed a pilot study and aimed to investigate the performance of mSEPT9, AFP, PIVKA-II and their combination in hepatic cirrhosis (HC) population.

Methods

A training cohort was established including 103 HCC and 114 HC patients. 10 ml blood was collected from each patient with K₂EDTA tubes, and 3-4 ml plasma was extracted for subsequent tests. The performance of mSEPT9, AFP, PIVKA-II and their combination was optimized by the training cohort. Test performance was prospectively validated with a validation cohort, including 51 HCC and 121 HC patients.

Results

At the optima

SUBMITTER: Zheng K 

PROVIDER: S-EPMC10388499 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature